Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, Wittrup KD.

Nucl Med Biol. 2011 Feb;38(2):223-33. doi: 10.1016/j.nucmedbio.2010.08.013. Epub 2010 Oct 27.

2.

Pretargeted radioimmunotherapy of cancer: progress step by step.

Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH.

J Nucl Med. 2003 Mar;44(3):400-11. Review.

3.

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.

Semin Nucl Med. 2010 May;40(3):190-203. doi: 10.1053/j.semnuclmed.2009.12.002. Review.

4.

Radioactive antibodies: a historical review of selective targeting and treatment of cancer.

Goldenberg DM, Sharkey RM.

Hosp Pract (1995). 2010;38(3):82-93. doi: 10.3810/hp.2010.06.300. Review.

PMID:
20890056
5.

Recent advances in pretargeted radioimmunotherapy.

Gruaz-Guyon A, Raguin O, Barbet J.

Curr Med Chem. 2005;12(3):319-38. Review.

PMID:
15723622
6.

Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK.

Q J Nucl Med. 1998 Dec;42(4):225-41. Review.

PMID:
9973838
7.

Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.

Dengl S, Sustmann C, Brinkmann U.

Immunol Rev. 2016 Mar;270(1):165-77. doi: 10.1111/imr.12386. Review.

8.
9.

Expanding room for tetrazine ligations in the in vivo chemistry toolbox.

Sečkutė J, Devaraj NK.

Curr Opin Chem Biol. 2013 Oct;17(5):761-7. doi: 10.1016/j.cbpa.2013.08.004. Epub 2013 Sep 7. Review.

Supplemental Content

Support Center